Anova is managing the delivery of Phase 1/2a study of DB107 at UCSF, USC, UCSD and with Denovo Biopharma DB107 is a proprietary gene therapy platform for the treatment of patients with newly diagnosed ...
LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, has ...
Anova completed enrollment of 550+ patients for an intermediate-sized, treatment IND in just six months, significantly reducing traditional site activation and patient enrolment timelines, and ...
LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San ...
LONDON & CHICAGO, March 05, 2025--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two ...
Anova completed enrollment of 550+ patients for an intermediate-sized, treatment IND in just six months, significantly reducing traditional site activation and patient enrolment timelines, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback